Oksi, J., Aalto, A., Säilä, P. et al. Real-world efficacy of bezlotoxumab for prevention of recurrent Clostridium difficile infection: a retrospective study of 46 patients in five university hospitals in Finland. Eur J Clin Microbiol Infect Dis 38, 1947–1952 (2019). https://doi.org/10.1007/s10096-019-03630-y
Real-world efficacy of bezlotoxumab for prevention of recurrent Clostridium difficile infection : a retrospective study of 46 patients in five university hospitals in Finland
|Author:||Oksi, Jarmo1; Aalto, A.2; Säilä, P.3;|
1Department of Infectious Diseases, Turku University Hospital and Turku University, SH-rak 4.krs, PO Box 52, 20521 Turku, Finland
2Department of Medicine, Kuopio University Hospital, Kuopio, Finland
3Department of Infectious Diseases, Tampere University Hospital, Tampere, Finland
4Department of Internal Medicine, Oulu University Hospital, Oulu, Finland
5Department of Infectious Diseases, Helsinki University Central Hospital, Helsinki, Finland
|Online Access:||PDF Full Text (PDF, 0.2 MB)|
|Persistent link:|| http://urn.fi/urn:nbn:fi-fe202003097628
|Publish Date:|| 2020-03-09
Reports on real-world experience on efficacy of bezlotoxumab (BEZ) has been lacking thus far. We retrospectively studied the efficacy and safety of BEZ in preventing the recurrence of Clostridium difficile infection (CDI) in five university hospitals in Finland. Seventy-three percent of our 46 patients remained free of recurrence in the following 3 months and the performance remained as 71% effective also among immunocompromised patients. In severe CDI, BEZ prevented recurrence in 63% of cases. From our study patients, 78% had three or more known risk factors for recurrence of CDI. Eight of our patients were waiting for fecal microbiota transplantation but after stopping the antibiotics that were continued to prevent recurrence of CDI and after receiving BEZ, all remained free of recurrence and did not need the procedure. Success with BEZ as an adjunctive treatment in preventing recurrence of CDI in high-risk patients may be rated as high. Among a subgroup of our patients, those already evaluated to be in need of fecal microbiota transplantation, BEZ seems to be an alternative option.
European journal of clinical microbiology & infectious diseases
|Pages:||1947 - 1952|
|Type of Publication:||
A1 Journal article – refereed
|Field of Science:||
3141 Health care science
Open access funding provided by University of Turku (UTU) including Turku University Central Hospital.
© The Authors 2019. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.